Azenta Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.57.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Azenta Inc's Score
Industry at a Glance
Industry Ranking
30 / 404
Overall Ranking
101 / 4563
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
38.571
Target Price
+10.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Azenta Inc Highlights
StrengthsRisks
Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 593.82M.
Fairly Valued
The company’s latest PE is -28.51, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.94M shares, increasing 0.01% quarter-over-quarter.
Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Ticker SymbolAZTA
CompanyAzenta Inc
CEOMarotta (John)
Websitehttps://www.azenta.com/
FAQs
What is the current price of Azenta Inc (AZTA)?
The current price of Azenta Inc (AZTA) is 34.750.
What is the symbol of Azenta Inc?
The ticker symbol of Azenta Inc is AZTA.
What is the 52-week high of Azenta Inc?
The 52-week high of Azenta Inc is 55.635.
What is the 52-week low of Azenta Inc?
The 52-week low of Azenta Inc is 23.910.
What is the market capitalization of Azenta Inc?
The market capitalization of Azenta Inc is 1.59B.
What is the net income of Azenta Inc?
The net income of Azenta Inc is -55.76M.
Is Azenta Inc (AZTA) currently rated as Buy, Hold, or Sell?
According to analysts, Azenta Inc (AZTA) has an overall rating of Buy, with a price target of 38.571.
What is the Earnings Per Share (EPS TTM) of Azenta Inc (AZTA)?
The Earnings Per Share (EPS TTM) of Azenta Inc (AZTA) is -1.219.